Interaction between sarcopenia and nonalcoholic fatty liver disease

Sarcopenia and nonalcoholic fatty liver disease (NAFLD) are common health problems related to aging. Despite the differences in their diagnostic methods, several cross-sectional and longitudinal studies have revealed the close link between sarcopenia and NAFLD. Sarcopenia and NAFLD are linked by several shared pathogenetic mechanisms, including insulin resistance, hormonal imbalance, systemic inflammation, myostatin and adiponectin dysregulation, nutritional deficiencies, and physical inactivity, thus implicating a bidirectional relationship between sarcopenia and NAFLD. However, there is not sufficient data to support a direct causal relationship between sarcopenia and NAFLD. Moreover, it is currently difficult to conclude whether sarcopenia is a risk factor for nonalcoholic steatohepatitis (NASH) or is a consequence of NASH. Therefore, this review intends to touch on the shared common mechanisms and the bidirectional relationship between sarcopenia and NAFLD.

[1]  U. Chang,et al.  Sarcopenia: Multiple factors need to be considered in cirrhosis. , 2022, Clinical and molecular hepatology.

[2]  S. Yim,et al.  Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis , 2022, Clinical and molecular hepatology.

[3]  E. Guallar,et al.  Nonalcoholic fatty liver disease and accelerated loss of skeletal muscle mass: A longitudinal cohort study , 2022, Hepatology.

[4]  Jeong Hwan Park,et al.  Myosteatosis, but not sarcopenia, predisposes NAFLD subjects to early steatohepatitis and fibrosis progression. , 2022, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  E. Roh,et al.  Impact of non-alcoholic fatty liver disease on the risk of sarcopenia: a nationwide multicenter prospective study , 2021, Hepatology International.

[6]  T. Kawaguchi,et al.  Leaky gut-derived tumor necrosis factor-α causes sarcopenia in patients with liver cirrhosis , 2021, Clinical and molecular hepatology.

[7]  Jin Mo Yang,et al.  Association between serum tumor necrosis factor-α and sarcopenia in liver cirrhosis , 2021, Clinical and molecular hepatology.

[8]  N. Lanthier,et al.  A dynamic association between myosteatosis and liver stiffness: Results from a prospective interventional study in obese patients , 2021, JHEP reports : innovation in hepatology.

[9]  B. Koo,et al.  Non‐alcoholic fatty liver disease and sarcopenia additively increase mortality: a Korean nationwide survey , 2021, Journal of cachexia, sarcopenia and muscle.

[10]  I. Leclercq,et al.  Muscle fat content is strongly associated with NASH: a longitudinal study in patients with morbid obesity. , 2021, Journal of hepatology.

[11]  I. Leclercq,et al.  Myosteatosis rather than sarcopenia associates with non‐alcoholic steatohepatitis in non‐alcoholic fatty liver disease preclinical models , 2020, Journal of cachexia, sarcopenia and muscle.

[12]  Han‐Chieh Lin,et al.  Muscle alterations are independently associated with significant fibrosis in patients with nonalcoholic fatty liver disease , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[13]  Sooyeon Oh,et al.  Sarcopenia and blood myokine levels as prognostic biomarkers in patients with liver cirrhosis or hepatocellular carcinoma , 2020, Clinical and molecular hepatology.

[14]  L. Gerber,et al.  Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease , 2020, JHEP reports : innovation in hepatology.

[15]  J. Ahn,et al.  The association of the serum levels of myostatin, follistatin, and interleukin-6 with sarcopenia, and their impacts on survival in patients with hepatocellular carcinoma , 2020, Clinical and molecular hepatology.

[16]  B. Koo,et al.  Association between muscle strength and advanced fibrosis in non‐alcoholic fatty liver disease: a Korean nationwide survey , 2020, Journal of cachexia, sarcopenia and muscle.

[17]  Shankuan Zhu,et al.  Low muscle mass and low muscle strength associate with nonalcoholic fatty liver disease. , 2020, Clinical nutrition.

[18]  M. Fukui,et al.  Relationship between nonalcoholic fatty liver disease and muscle quality as well as quantity evaluated by computed tomography , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[19]  A. Montano‐Loza,et al.  Clinical relevance of skeletal muscle abnormalities in patients with cirrhosis. , 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[20]  F. Marra,et al.  Myostatin regulates the fibrogenic phenotype of hepatic stellate cells via c-jun N-terminal kinase activation. , 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[21]  L. Ferrucci,et al.  Sarcopenia: A Time for Action. An SCWD Position Paper , 2019, Journal of cachexia, sarcopenia and muscle.

[22]  J. Park,et al.  Association of low skeletal muscle mass with advanced liver fibrosis in patients with non‐alcoholic fatty liver disease , 2019, Journal of gastroenterology and hepatology.

[23]  Donghee Kim,et al.  Associations between sarcopenia and nonalcoholic fatty liver disease and advanced fibrosis in the USA. , 2019, European journal of gastroenterology & hepatology.

[24]  I. Leclercq,et al.  Emerging awareness on the importance of skeletal muscle in liver diseases: time to dig deeper into mechanisms! , 2019, Clinical science.

[25]  C. Kennedy,et al.  Differing Impact of Sarcopenia and Frailty in Nonalcoholic Steatohepatitis and Alcoholic Liver Disease , 2019, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[26]  Hong-Kyu Kim,et al.  Age-Related Decrease in Skeletal Muscle Mass Is an Independent Risk Factor for Incident Nonalcoholic Fatty Liver Disease: A 10-Year Retrospective Cohort Study , 2018, Gut and liver.

[27]  René Rizzoli,et al.  Sarcopenia: revised European consensus on definition and diagnosis , 2018, Age and ageing.

[28]  Yaw-Wen Chang,et al.  Nonalcoholic fatty liver disease and sarcopenia in a Western population (NHANES III): The importance of sarcopenia definition. , 2017, Clinical nutrition.

[29]  J. Kao,et al.  Sarcopenia and chronic liver diseases , 2018, Expert review of gastroenterology & hepatology.

[30]  Sang-Man Jin,et al.  Relationship Between Relative Skeletal Muscle Mass and Nonalcoholic Fatty Liver Disease: A 7‐Year Longitudinal Study , 2018, Hepatology.

[31]  Ke Xu,et al.  Sarcopenia Contributes to the Progression of Nonalcoholic Fatty Liver Disease- Related Fibrosis: A Meta-Analysis , 2018, Digestive Diseases.

[32]  Q. Xiao,et al.  The Relationship between NAFLD and Sarcopenia in Elderly Patients , 2018, Canadian journal of gastroenterology & hepatology.

[33]  A. Allen,et al.  Sarcopenia in hiding: The risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis , 2017, Hepatology.

[34]  Richard W. Bohannon,et al.  Relationship between sarcopenia and physical activity in older people: a systematic review and meta-analysis , 2017, Clinical interventions in aging.

[35]  B. Carson.  The Potential Role of Contraction-Induced Myokines in the Regulation of Metabolic Function for the Prevention and Treatment of Type 2 Diabetes , 2017, Front. Endocrinol..

[36]  G. Marchesini,et al.  Sarcopenia is associated with severe liver fibrosis in patients with non‐alcoholic fatty liver disease , 2017, Alimentary pharmacology & therapeutics.

[37]  M. Chang,et al.  Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. , 2017, Journal of hepatology.

[38]  Ricardo Henao,et al.  Vitamin D is Not Associated With Severity in NAFLD: Results of a Paired Clinical and Gene Expression Profile Analysis , 2016, The American Journal of Gastroenterology.

[39]  J. Torres,et al.  Diet-Induced Nonalcoholic Fatty Liver Disease Is Associated with Sarcopenia and Decreased Serum Insulin-Like Growth Factor-1 , 2016, Digestive Diseases and Sciences.

[40]  James E. Nelson,et al.  Vitamin D Deficiency Is Associated With Increased Risk of Non-alcoholic Steatohepatitis in Adults With Non-alcoholic Fatty Liver Disease: Possible Role for MAPK and NF-κB? , 2016, The American Journal of Gastroenterology.

[41]  E. Kang,et al.  Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008‐2011) , 2016, Hepatology.

[42]  Kyungdo Han,et al.  Low skeletal muscle mass is associated with non-alcoholic fatty liver disease in Korean adults: the Fifth Korea National Health and Nutrition Examination Survey. , 2016, Hepatobiliary & pancreatic diseases international : HBPD INT.

[43]  Q. Pang,et al.  Sarcopenia and nonalcoholic fatty liver disease: New evidence for low vitamin D status contributing to the link , 2016, Hepatology.

[44]  M. Sawyer,et al.  Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis , 2015, Journal of cachexia, sarcopenia and muscle.

[45]  E. Kang,et al.  Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008-2011). , 2015, Journal of hepatology.

[46]  S. Kim,et al.  Irisin, a Novel Myokine, Regulates Glucose Uptake in Skeletal Muscle Cells via AMPK. , 2015, Molecular endocrinology.

[47]  A. Boschero,et al.  Exercise increases pancreatic β‐cell viability in a model of type 1 diabetes through IL‐6 signaling , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[48]  T. Bertsch,et al.  Sarcopenic obesity: molecular clues to a better understanding of its pathogenesis? , 2015, Biogerontology.

[49]  G. Biolo,et al.  Muscle contractile and metabolic dysfunction is a common feature of sarcopenia of aging and chronic diseases: from sarcopenic obesity to cachexia. , 2014, Clinical nutrition.

[50]  S. Yano,et al.  Active vitamin D possesses beneficial effects on the interaction between muscle and bone. , 2014, Biochemical and biophysical research communications.

[51]  S. Dasarathy.  Is the adiponectin‐AMPK‐mitochondrial axis involved in progression of nonalcoholic fatty liver disease? , 2014, Hepatology.

[52]  A. McCullough,et al.  Presence of sarcopenia (muscle wasting) in patients with nonalcoholic steatohepatitis , 2014, Hepatology.

[53]  M. Sawyer,et al.  Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantation , 2014, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[54]  M. D. de Angelis,et al.  Secretome profiling of primary human skeletal muscle cells. , 2014, Biochimica et biophysica acta.

[55]  H. J. Yoo,et al.  Relationship between sarcopenia and nonalcoholic fatty liver disease: The Korean Sarcopenic Obesity Study , 2014, Hepatology.

[56]  T. Hornberger,et al.  Faculty Opinions recommendation of Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. , 2014 .

[57]  M. Egerman,et al.  Signaling pathways controlling skeletal muscle mass , 2013, Critical reviews in biochemistry and molecular biology.

[58]  Rohit Loomba,et al.  The global NAFLD epidemic , 2013, Nature Reviews Gastroenterology &Hepatology.

[59]  Evelyn Wong,et al.  Diabetes and risk of physical disability in adults: a systematic review and meta-analysis. , 2013, The lancet. Diabetes & endocrinology.

[60]  A. Goldberg,et al.  Myostatin/activin pathway antagonism: molecular basis and therapeutic potential. , 2013, The international journal of biochemistry & cell biology.

[61]  Hirokazu Takahashi,et al.  Severity of non‐alcoholic steatohepatitis is associated with substitution of adipose tissue in skeletal muscle , 2013, Journal of gastroenterology and hepatology.

[62]  Zheng Chen,et al.  Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. , 2013, Journal of hepatology.

[63]  E. Guallar,et al.  Meta‐analysis: vitamin D and non‐alcoholic fatty liver disease , 2013, Alimentary pharmacology & therapeutics.

[64]  R. Moreno-otero,et al.  Pathogenesis, diagnosis and treatment of non-alcoholic fatty liver disease. , 2013, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[65]  G. Johannsson,et al.  The GH/IGF-1 axis in obesity: pathophysiology and therapeutic considerations , 2013, Nature Reviews Endocrinology.

[66]  J. Eckel,et al.  Identification and Validation of Novel Contraction-Regulated Myokines Released from Primary Human Skeletal Muscle Cells , 2013, PloS one.

[67]  J. Moreno-Navarrete,et al.  Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. , 2013, The Journal of clinical endocrinology and metabolism.

[68]  M. Holick,et al.  The roles of vitamin D in skeletal muscle: form, function, and metabolism. , 2013, Endocrine reviews.

[69]  M. Sandri,et al.  Cellular and molecular mechanisms of muscle atrophy , 2013, Disease Models & Mechanisms.

[70]  W. Ling,et al.  Vitamin D attenuates high fat diet–induced hepatic steatosis in rats by modulating lipid metabolism , 2012, European journal of clinical investigation.

[71]  W. Hoogaars,et al.  Interference with myostatin/ActRIIB signaling as a therapeutic strategy for Duchenne muscular dystrophy. , 2012, Current gene therapy.

[72]  James E. Nelson,et al.  Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and toll‐like receptor activation , 2012, Hepatology.

[73]  I. Bautmans,et al.  Chronic low-grade inflammation and age-related sarcopenia , 2012, Current opinion in clinical nutrition and metabolic care.

[74]  M. Gassmann,et al.  Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells , 2011, Nature Medicine.

[75]  S. Morini,et al.  Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes , 2011, BMC medicine.

[76]  Keith C. Norris,et al.  1,25(OH)2vitamin D3 stimulates myogenic differentiation by inhibiting cell proliferation and modulating the expression of promyogenic growth factors and myostatin in C2C12 skeletal muscle cells. , 2011, Endocrinology.

[77]  R. Ahima,et al.  Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy. , 2011, The American journal of pathology.

[78]  P. Gluckman,et al.  Myostatin-deficient mice exhibit reduced insulin resistance through activating the AMP-activated protein kinase signalling pathway , 2011, Diabetologia.

[79]  Bente Klarlund Pedersen,et al.  Muscles and their myokines , 2011, Journal of Experimental Biology.

[80]  A. Kahraman,et al.  Obesity Affects the Liver – The Link between Adipocytes and Hepatocytes , 2010, Digestion.

[81]  H. J. Yoo,et al.  Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes: The Korean Sarcopenic Obesity Study (KSOS) (Diabetes Care (2010) 33, (1497-1499)) , 2010 .

[82]  A. Hevener,et al.  Sarcopenia Exacerbates Obesity-Associated Insulin Resistance and Dysglycemia: Findings from the National Health and Nutrition Examination Survey III , 2010, PloS one.

[83]  M. Cesari,et al.  ACE-inhibition and physical function: results from the Trial of Angiotensin-Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. , 2010, Journal of the American Medical Directors Association.

[84]  R. DeFronzo,et al.  Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes , 2009, Diabetes Care.

[85]  J. George,et al.  Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss , 2009, Hepatology.

[86]  P. Cawthon,et al.  Sarcopenia: etiology, clinical consequences, intervention, and assessment , 2009, Osteoporosis International.

[87]  S. Fujita,et al.  Supraphysiological hyperinsulinaemia is necessary to stimulate skeletal muscle protein anabolism in older adults: evidence of a true age-related insulin resistance of muscle protein metabolism , 2009, Diabetologia.

[88]  I. Janssen,et al.  Sarcopenic-obesity and cardiovascular disease risk in the elderly , 2009, The journal of nutrition, health & aging.

[89]  J. Chiang,et al.  Mechanism of Vitamin D Receptor Inhibition of Cholesterol 7α-Hydroxylase Gene Transcription in Human Hepatocytes , 2009, Drug Metabolism and Disposition.

[90]  H. Tilg,et al.  Insulin resistance, inflammation, and non-alcoholic fatty liver disease , 2008, Trends in Endocrinology & Metabolism.

[91]  L. Ceglia.  Vitamin D and skeletal muscle tissue and function. , 2008, Molecular aspects of medicine.

[92]  J. Fisher,et al.  Skeletal Muscle Insulin Resistance: Roles of Fatty Acid Metabolism and Exercise , 2008, Physical Therapy.

[93]  M. Febbraio,et al.  Muscle as an endocrine organ: focus on muscle-derived interleukin-6. , 2008, Physiological reviews.

[94]  W. Willett,et al.  Vitamin D and Health: Perspectives From Mice and Man , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[95]  A. Feldstein,et al.  Increased Hepatic and Circulating Interleukin-6 Levels in Human Nonalcoholic Steatohepatitis , 2008, The American Journal of Gastroenterology.

[96]  Shana Suzuki,et al.  Enhanced muscle by myostatin propeptide increases adipose tissue adiponectin, PPAR-alpha, and PPAR-gamma expressions. , 2008, Biochemical and biophysical research communications.

[97]  J. Girard,et al.  Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. , 2008, The Journal of clinical investigation.

[98]  S. Fujita,et al.  Aerobic Exercise Overcomes the Age-Related Insulin Resistance of Muscle Protein Metabolism by Improving Endothelial Function and Akt/Mammalian Target of Rapamycin Signaling , 2007, Diabetes.

[99]  F. Lönnqvist,et al.  Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle. , 2006, Molecular endocrinology.

[100]  D. James,et al.  Interleukin-6 Increases Insulin-Stimulated Glucose Disposal in Humans and Glucose Uptake and Fatty Acid Oxidation In Vitro via AMP-Activated Protein Kinase , 2006, Diabetes.

[101]  H. Tilg,et al.  Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. , 2006, Gastroenterology.

[102]  Y. Boirie,et al.  Insulin resistance: a contributing factor to age-related muscle mass loss? , 2005, Diabetes & metabolism.

[103]  S. Bhasin,et al.  Myostatin inhibits myogenesis and promotes adipogenesis in C3H 10T(1/2) mesenchymal multipotent cells. , 2005, Endocrinology.

[104]  C. Carlberg,et al.  The human peroxisome proliferator-activated receptor delta gene is a primary target of 1alpha,25-dihydroxyvitamin D3 and its nuclear receptor. , 2005, Journal of molecular biology.

[105]  B. Saltin,et al.  Searching for the exercise factor: is IL-6 a candidate? , 2004, Journal of Muscle Research & Cell Motility.

[106]  Marjolein Visser,et al.  Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. , 2003, The Journal of clinical endocrinology and metabolism.

[107]  J. Wrana,et al.  Myostatin Signals through a Transforming Growth Factor β-Like Signaling Pathway To Block Adipogenesis , 2003, Molecular and Cellular Biology.

[108]  B. Pedersen,et al.  The effect of graded exercise on IL‐6 release and glucose uptake in human skeletal muscle , 2003, The Journal of physiology.

[109]  S. Uchida,et al.  Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase , 2002, Nature Medicine.

[110]  B. Saltin,et al.  Production of interleukin‐6 in contracting human skeletal muscles can account for the exercise‐induced increase in plasma interleukin‐6 , 2000, The Journal of physiology.

[111]  Se-Jin Lee,et al.  Myostatin and the control of skeletal muscle mass. , 1999, Current opinion in genetics & development.

[112]  D. Gerrard,et al.  Myostatin expression in porcine tissues: tissue specificity and developmental and postnatal regulation. , 1998, American journal of physiology. Regulatory, integrative and comparative physiology.

[113]  G. Reaven.  Banting lecture 1988. Role of insulin resistance in human disease. , 1988, Diabetes.